D Groheux

Summary

Country: France

Publications

  1. ncbi request reprint [Interests and perspectives of PET-CT for breast cancer: review of the literature]
    David Groheux
    Service de médecine nucléaire et centre TEP, Hopital Saint Louis, Paris
    Bull Cancer 94:658-68. 2007
  2. doi request reprint Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, University of Paris VII, Paris, France
    Nucl Med Commun 30:926-33. 2009
  3. doi request reprint (18)F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
    Eur J Nucl Med Mol Imaging 43:983-93. 2016
  4. doi request reprint 18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen
    David Groheux
    Department of Nuclear Medicine, APHP, Saint Louis Hospital, Paris, France University Paris Diderot, PRES Paris Cité, INSERM CNRS UMR944 7212, Paris, France
    J Nucl Med 57:536-43. 2016
  5. doi request reprint 18F-FDG PET/CT for Staging and Restaging of Breast Cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 57:17S-26S. 2016
  6. doi request reprint Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 56:824-31. 2015
  7. doi request reprint ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France Doctoral School of Biology and Biotechnology, University Institute of Hematology, University of Paris VII, Paris, France Electronic address
    Eur J Radiol 83:1925-33. 2014
  8. doi request reprint Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer
    D Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
    Eur J Nucl Med Mol Imaging 42:377-85. 2015
  9. doi request reprint Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France B2T, Doctoral School, IUH, University of Paris VII, France Electronic address
    Eur J Cancer 50:1864-71. 2014
  10. pmc HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
    D Groheux
    Nuclear Medicine, Saint Louis Hospital, 1 avenue Claude Vellefaux, Paris 75475, France
    Br J Cancer 109:1157-64. 2013

Detail Information

Publications22

  1. ncbi request reprint [Interests and perspectives of PET-CT for breast cancer: review of the literature]
    David Groheux
    Service de médecine nucléaire et centre TEP, Hopital Saint Louis, Paris
    Bull Cancer 94:658-68. 2007
    ..Nevertheless, the data of the literature appear insufficient to recommend it in current practice. It is the same way for the prognostic interest...
  2. doi request reprint Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, University of Paris VII, Paris, France
    Nucl Med Commun 30:926-33. 2009
    ....
  3. doi request reprint (18)F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
    Eur J Nucl Med Mol Imaging 43:983-93. 2016
    ..The results of a multicentre trial that used early metabolic response on (18)F-FDG PET/CT as a means to select poor responders to adapt neoadjuvant treatment have recently been published. Other trials are ongoing or being planned. ..
  4. doi request reprint 18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen
    David Groheux
    Department of Nuclear Medicine, APHP, Saint Louis Hospital, Paris, France University Paris Diderot, PRES Paris Cité, INSERM CNRS UMR944 7212, Paris, France
    J Nucl Med 57:536-43. 2016
    ..We evaluated the association between metabolic response after 2 cycles of neoadjuvant chemotherapy, pCR, and outcome in patients receiving 2 different anthracycline-based regimens (conventional and intensified)...
  5. doi request reprint 18F-FDG PET/CT for Staging and Restaging of Breast Cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 57:17S-26S. 2016
    ..We conclude with some recommendations for clinical practice and future research. ..
  6. doi request reprint Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 56:824-31. 2015
    ....
  7. doi request reprint ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France Doctoral School of Biology and Biotechnology, University Institute of Hematology, University of Paris VII, Paris, France Electronic address
    Eur J Radiol 83:1925-33. 2014
    ..The aim of this study was to analyze the performance of [18F]fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in staging, restaging, and therapy response assessment...
  8. doi request reprint Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer
    D Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
    Eur J Nucl Med Mol Imaging 42:377-85. 2015
    ..The aim of this study was to determine if pretreatment (18)F-FDG PET/CT staging and pathological findings after NAC could together allow stratification of patients into prognostic groups...
  9. doi request reprint Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France B2T, Doctoral School, IUH, University of Paris VII, France Electronic address
    Eur J Cancer 50:1864-71. 2014
    ..This prospective study was designed and powered to investigate the ability of interim (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)FDG-PET/CT) to predict pathology outcomes to NAC early during treatment...
  10. pmc HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment
    D Groheux
    Nuclear Medicine, Saint Louis Hospital, 1 avenue Claude Vellefaux, Paris 75475, France
    Br J Cancer 109:1157-64. 2013
    ..We investigated the ability of interim positron emission tomography (PET) regarding early prediction of pathology outcomes...
  11. doi request reprint Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy
    David Groheux
    Department of Nuclear Medicine, St Louis Hospital, Paris, France
    Cancer 119:1960-8. 2013
    ....
  12. doi request reprint Performance of FDG PET/CT in the clinical management of breast cancer
    David Groheux
    Department of Nuclear Medicine and Department of Medical Oncology, Breast Diseases Unit, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Radiology 266:388-405. 2013
    ....
  13. doi request reprint 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 54:5-11. 2013
    ..We prospectively investigated the impact of (18)F-FDG PET/CT at initial staging in this clinical setting and compared PET/CT performance with that of conventional distant work-up...
  14. pmc Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer
    David Groheux
    Service de Medecine Nucleaire, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, 1 Ave Claude Vellefaux, 75475 Paris Cedex 10, France
    J Natl Cancer Inst 104:1879-87. 2012
    ..This study prospectively evaluated the yield of fluorodeoxyglucose positron emission tomography/computed tomography ((18)FDG-PET-CT) in patients with clinical stages II and III breast cancer and the impact of PET-CT results on prognosis...
  15. doi request reprint Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 53:249-54. 2012
    ..Triple-negative breast cancer, an aggressive subtype, represents 15% of invasive breast tumors. This prospective study investigated whether early changes in (18)F-FDG tumor uptake during neoadjuvant chemotherapy (NAC) can predict outcomes...
  16. doi request reprint Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer
    David Groheux
    Department of Nuclear Medicine, Breast Diseases Unit, Saint Louis Hospital, Paris, France
    Int J Radiat Oncol Biol Phys 71:695-704. 2008
    ..To investigate the potential effect of using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in the initial assessment of patients with clinical Stage II or III breast cancer...
  17. doi request reprint [Advantages of PET-CT in the work-up of cervical cancer]
    D Groheux
    Service de Medecine Nucleaire, pôle PIC, Hopital Saint Louis, Assistance publique des Hôpitaux de Paris APHP, 1 avenue Claude Vellefaux, Paris Cedex 10, France
    Bull Cancer 96:199-211. 2009
    ..PET is useful to evaluate therapy, but its exact role in this issue remains to be further refined. Finally, PET-CT can document early recurrence of disease...
  18. doi request reprint [PET/CT in breast cancer: an update]
    D Groheux
    Service de Medecine Nucleaire, Pôle Imagerie Cancérologie PIC, Hopital Saint Louis, Assistance Publique des Hopitaux de Paris, 1, avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Bull Cancer 96:1053-70. 2009
    ..18FDG-PET/CT could thus become an unavoidable modality to answer various clinical situations...
  19. ncbi request reprint [PET-CT for evaluation of the solitary pulmonary nodule: an update]
    D Groheux
    Service de Medecine Nucleaire, Pôle Imagerie Cancérologie PIC, Hopital Saint Louis, Assistance Publique des Hopitaux de Paris, Paris, France
    Rev Mal Respir 26:1041-55. 2009
    ..Positron emission tomography (PET) with 18F-FDG has become an important tool for the characterization of solitary pulmonary nodules (SPN)...
  20. doi request reprint Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris, France
    Eur J Nucl Med Mol Imaging 38:426-35. 2011
    ..Only women with tumours larger than 20 mm (T2-T4) were included in order to minimize bias of partial volume effect...
  21. doi request reprint The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study
    David Groheux
    Department of Nuclear Medicine, Saint Louis Hospital, Paris, France
    J Nucl Med 52:1526-34. 2011
    ..The purpose of this study was to prospectively evaluate the role of (18)F-FDG PET/CT in patients with stage IIA, IIB, or IIIA breast cancer...
  22. doi request reprint [Sentinel node biopsy in breast cancer]
    E Hindie
    Service de Medecine Nucleaire, Hopital Saint Louis, Assistance Publique des Hopitaux de Paris, 1, avenue Claude Vellefaux, 75475 Paris Cedex 10, France
    Bull Cancer 96:713-25. 2009
    ..can benefit from the sentinel node technique? 2) What is the optimal methodology? 3) What is the prognostic significance of micrometastases and of isolated tumour cells? 4) What attention should be given to extra-axillary drainage?..